Background: Lichen planus (LP) is animmune mediated inflammatorydiseaseof skin and mucous membranes without a clear etiology. Interleukin-6 (IL-6) is a pro-inflammatory cytokinewith variousbiologicaland pathological impactson immunity, acute phase response andinflammation. ExcessiveIL-6production can play a role in the pathogenesis of several pathological conditionslike psoriasis. Aim:This study aimed to evaluate serum IL-6 levels inLP patients alongwithassessment ofitscorrelation with disease severity. Patients and methods: Twenty-one adult patients with LP as well astwenty-one healthy adult controls were enrolled in the study. The total score of LP severity was estimated for all patientsby calculation of the affected body surface area in cutaneous LP patients and clinical scoring system with visual analogue scale for pain assessment for oral LP.Serum IL-6 levels were measured in all participants using enzyme-linked immunosorbent assay. Results:The mean serumIL-6 levels were significantly higher in patients than controls (P < .002). A positive correlation wasnoticed between serum IL-6 with both cutaneous LP (P <0.004) and oral LP (P <0.005) severities. Conclusion:Serum IL-6may be a potential biomarker for LP as it was greater in LP patients than controls and waspositivelycorrelated with disease severity.Further studies are necessary to evaluate the therapeutic efficacy of IL-6 blockade that could be beneficial in LP management.